USP22 and hepatocellular carcinoma: For instance, resistance in hepatocellular carcinoma involves the p-MYH9/USP22 axis stabilizing HIF-1alpha, promoting stemness and lenvatinib resistance, while in pancreatic cancer, targeting MXD1 overcomes trametinib resistance [31].